Dr. Doering is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3991 Dutchmans Ln
4th Floor
Louisville, KY 40207Phone+1 502-899-3366Fax+1 502-899-3455
Summary
- I am a board certified Gynecologic Oncologist, specializing in the medical and surgical management of gynecologic malignancies. I also recently completed training in Medical Acupuncture for Physicians
Education & Training
- Helms Medical InstitutePost-Doctoral Fellowship, 2017 - 2018
- National Capital ConsortiumFellowship, Gynecologic Oncology, 1986 - 1989
- National Capital ConsortiumResidency, Obstetrics and Gynecology, 1980 - 1984
- University of Alabama School of MedicineClass of 1980
- Vanderbilt UniversityBA, German, Cum laude, 1972 - 1976
Certifications & Licensure
- KY State Medical License 1991 - 2025
- IN State Medical License 1994 - 2021
- MD State Medical License 1984 - 1994
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow (FACS) American College of Surgeons
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Publications & Presentations
PubMed
- Feasibility of Risk Reducing Salpingo-Oophorectomy at the Time of Abdominal Surgery for Correction of Pelvic Organ Prolapse and Urinary Incontinence.Ali Azadi, James Bradley, Greg J Marchand, Douglas J. Lorenz, David Doering
Gynecology and Minimally Invasive Therapy. 2021-01-01 - Polypropylene Mesh Sling for Stress Urinary Incontinence: Does Memory Shaping of the Polypropylene Mesh Matter?Andrew Doering, Ali Azadi, David Doering, Donald R. Ostergard
Surgical Technology International. 2017-12-22 - 16 citationsSingle-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study.D.S. McMeekin, A. Lisyanskaya, Marta A. Crispens, Amit M. Oza, Patricia S. Braly
Gynecologic Oncology. 2009-08-01
Professional Memberships
- Member
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: